Key result
Alirocumab added to high-intensity statin therapy significantly reduced percent atheroma volume compared with placebo (difference, -1.21%; 95% CI, -1.78% to -0.65%; P<.001).
Why the study?
Statins can halt coronary atherosclerosis progression, but the effect of adding the PCSK9 inhibitor alirocumab to statin therapy on coronary plaque burden and composition remained largely unknown.
Does alirocumab added to high-intensity statin therapy reduce coronary atherosclerosis in patients with acute myocardial infarction?
RCT (n=300)
Double-blind
randomized
Yes
Does alirocumab added to high-intensity statin therapy reduce coronary atherosclerosis in patients with acute myocardial infarction?
Mean Difference: -1.21 (95% CI -1.78–-0.65)
Absolute Event Rate: -2.13% vs -0.92%
p-value: p=<.001
In patients with acute myocardial infarction, the addition of alirocumab to high-intensity statin therapy resulted in significantly greater coronary plaque regression in non-infarct-related arteries after 52 weeks.
No takes yet. Share an insight, caveat, or question.
May support earlier LLT intensification after AMI; extends PCSK9-inhibitor plaque-imaging evidence from stable CAD into ACS.
Räber et al. (2022) conducted an RCT in Acute myocardial infarction (n=300). Alirocumab vs. Placebo was evaluated on Change in IVUS-derived percent atheroma volume from baseline to week 52 (MD -1.21%, 95% CI -1.78 to -0.65, p=<.001). Alirocumab added to high-intensity statin therapy significantly reduced percent atheroma volume compared with placebo (difference, -1.21%; 95% CI, -1.78% to -0.65%; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: